TY - JOUR
T1 - A Pressure Test to Make 10 Molecules in 90 Days
T2 - External Evaluation of Methods to Engineer Biology
AU - Casini, Arturo
AU - Chang, Fang Yuan
AU - Eluere, Raissa
AU - King, Andrew M.
AU - Young, Eric M.
AU - Dudley, Quentin M.
AU - Karim, Ashty
AU - Pratt, Katelin
AU - Bristol, Cassandra
AU - Forget, Anthony
AU - Ghodasara, Amar
AU - Warden-Rothman, Robert
AU - Gan, Rui
AU - Cristofaro, Alexander
AU - Borujeni, Amin Espah
AU - Ryu, Min Hyung
AU - Li, Jian
AU - Kwon, Yong Chan
AU - Wang, He
AU - Tatsis, Evangelos
AU - Rodriguez-Lopez, Carlos
AU - O'Connor, Sarah
AU - Medema, Marnix H.
AU - Fischbach, Michael A.
AU - Jewett, Michael C.
AU - Voigt, Christopher
AU - Gordon, D.B.
PY - 2018/3/28
Y1 - 2018/3/28
N2 - Centralized facilities for genetic engineering, or "biofoundries", offer the potential to design organisms to address emerging needs in medicine, agriculture, industry, and defense. The field has seen rapid advances in technology, but it is difficult to gauge current capabilities or identify gaps across projects. To this end, our foundry was assessed via a timed "pressure test", in which 3 months were given to build organisms to produce 10 molecules unknown to us in advance. By applying a diversity of new approaches, we produced the desired molecule or a closely related one for six out of 10 targets during the performance period and made advances toward production of the others as well. Specifically, we increased the titers of 1-hexadecanol, pyrrolnitrin, and pacidamycin D, found novel routes to the enediyne warhead underlying powerful antimicrobials, established a cell-free system for monoterpene production, produced an intermediate toward vincristine biosynthesis, and encoded 7802 individually retrievable pathways to 540 bisindoles in a DNA pool. Pathways to tetrahydrofuran and barbamide were designed and constructed, but toxicity or analytical tools inhibited further progress. In sum, we constructed 1.2 Mb DNA, built 215 strains spanning five species (Saccharomyces cerevisiae, Escherichia coli, Streptomyces albidoflavus, Streptomyces coelicolor, and Streptomyces albovinaceus), established two cell-free systems, and performed 690 assays developed in-house for the molecules.
AB - Centralized facilities for genetic engineering, or "biofoundries", offer the potential to design organisms to address emerging needs in medicine, agriculture, industry, and defense. The field has seen rapid advances in technology, but it is difficult to gauge current capabilities or identify gaps across projects. To this end, our foundry was assessed via a timed "pressure test", in which 3 months were given to build organisms to produce 10 molecules unknown to us in advance. By applying a diversity of new approaches, we produced the desired molecule or a closely related one for six out of 10 targets during the performance period and made advances toward production of the others as well. Specifically, we increased the titers of 1-hexadecanol, pyrrolnitrin, and pacidamycin D, found novel routes to the enediyne warhead underlying powerful antimicrobials, established a cell-free system for monoterpene production, produced an intermediate toward vincristine biosynthesis, and encoded 7802 individually retrievable pathways to 540 bisindoles in a DNA pool. Pathways to tetrahydrofuran and barbamide were designed and constructed, but toxicity or analytical tools inhibited further progress. In sum, we constructed 1.2 Mb DNA, built 215 strains spanning five species (Saccharomyces cerevisiae, Escherichia coli, Streptomyces albidoflavus, Streptomyces coelicolor, and Streptomyces albovinaceus), established two cell-free systems, and performed 690 assays developed in-house for the molecules.
U2 - 10.1021/jacs.7b13292
DO - 10.1021/jacs.7b13292
M3 - Article
AN - SCOPUS:85044667526
SN - 0002-7863
VL - 140
SP - 4302
EP - 4316
JO - Journal of the American Chemical Society
JF - Journal of the American Chemical Society
IS - 12
ER -